OBJECTIVE: Magnesium may have a role in neuroprotection in neonatal hypoxic-ischemic encephalopathy (HIE). The objective of this study was to systematically review the efficacy and safety of postnatal magnesium therapy in newborns with HIE. STUDY DESIGN: MEDLINE, EMBASE, CINAHL and CCRCT were searched for studies of magnesium for HIE. Randomized controlled trials that compared magnesium to control in newborns with HIE were selected. The primary outcome was a composite outcome of death or moderate-to-severe neurodevelopmental disability at 18 months. When appropriate, meta-analyses were conducted using random effects model and risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. RESULT: Five studies with sufficient quality were included. There was no difference in the primary outcome between the magnesium and the control groups (RR 0.81, 95% CI 0.36 to 1.84). There was significant reduction in the unfavorable short-term composite outcome (RR 0.48, 95% CI 0.30 to 0.77) but no difference in mortality (RR 1.39, 95% CI 0.85 to 2.27), seizures (RR 0.84, 95% CI 0.59 to 1.19) or hypotension (RR 1.28, 95% CI 0.69 to 2.38) between the magnesium and the control groups. CONCLUSION: The improvement in short-term outcomes without significant increase in side effects indicate the need for further trials to determine if there are long-term benefits of magnesium and to confirm its safety. Mortality was statistically insignificant between the magnesium and the control groups. However, the trend toward increase in mortality in the magnesium group is a major clinical concern and should be monitored closely in future trials.
INTRODUCTION
Perinatal asphyxia remains a major cause of long-term sensorineural impairments and disabilities; [1] [2] [3] with an incidence of 1 to 2 per 1000 births in developed countries and up to 5 per 1000 births in developing countries. [4] [5] [6] Despite the improvement in clinical outcomes with therapeutic hypothermia, 50% of newborns with moderate-to-severe hypoxic-ischemic encephalopathy (HIE) will die or survive with major disabilities including cerebral palsy and major developmental delay. 7 Therefore, the search is ongoing for adjuvant treatment to therapeutic hypothermia. 8, 9 Increasing knowledge of the pathological processes in post-asphyxial neuronal injury, cell death and secondary apoptosis has led to exploration of different avenues for prevention of secondary neuronal injury. 10, 11 During asphyxia, there is excessive release and reduced uptake of glutamate, which is an excitatory neurotransmitter. Glutamate acts on the N-methyl-D-aspartate (NMDA) receptors, a postsynaptic ion channel in the brain. High concentrations of glutamate open NMDA channels, allowing excessive calcium influx into the neurons and induce irreversible neuronal injury. 12 NMDA receptor antagonists block calcium ion entry into the cell and preserve neuronal function and structure. 13, 14 Magnesium ion gates the NMDA channels in a voltage-dependent manner and may protect the developing brain from the NMDA receptor-mediated injury. 15 Thus, magnesium was proposed for clinical use to combat glutamate excitotoxicity associated with birth asphyxia. 16 The objective of this review was to systematically review the efficacy and safety of postnatal magnesium therapy in newborns with HIE and to determine whether, for infants born at or after 35 weeks gestation with HIE, magnesium supplementation given within the first 24 h after birth improves survival or neurodevelopmental outcome compared to controls, from randomized controlled trials.
METHODS

Study selection
Randomized controlled trials that compared magnesium to placebo or no therapy to treat newbornsX35 weeks gestation with HIE were included. Studies that had significant methodological limitations and duplicate reports not providing additional information were excluded.
Type of intervention
Magnesium given within the first 24 h after birth as a neuroprotective agent in any dose and by any route. AND (brain isch(a)emia or cerebral isch(a)emia or isch(a)emic encephalopathy or isch(a)emic stroke or isch(a)emic attack or neural isch(a)emia or brain infarction or brain (o)edema) AND (neonate or newborn or new-born). This search was then combined using OR with a search for (magnesium or magnesium sulfate) AND (asphyxia neonatorum or neonatal hypoxia). Database subject headings were exploded, when applicable, to include narrower terms. In all databases, truncation symbols were used in text word searches to capture variant endings of the search terms as well as variant spelling. Adjacency operators were used in text word searches to maximize retrieval. To retrieve the neonatal literature, ages were searched both as text words as well as through the database-specific subject headings and limits. No language restrictions were applied.
Study identification, quality assessment and data extraction All titles and abstracts identified as potentially relevant by the literature search were assessed independently by two reviewers (MT and K-SL) for eligibility. Any disagreement on the studies to be selected was resolved by the third reviewer (PSS). Subsequently, the full texts for potentially eligible studies were reviewed against the predefined criteria for risk of bias. The methodological quality of the studies was assessed using the risk of bias assessment tool as recommended by the Cochrane Neonatal Review Group. 17 The domains of assessment included adequate sequence generation, allocation concealment, blinding of intervention, blinding of outcome assessors, incomplete outcome data, selective outcome reporting and the likelihood of other biases. There were three answers to these questions yes, no and unclear. An overall degree of bias (unlikely, low, moderate and high) was assigned for each study considering biases in all domains. Studies that had a high risk of bias were considered to have significant limitations and were excluded. Data were extracted by two reviewers (MT and K-SL) on a predefined data extraction form.
Outcomes measures
The primary outcome was a composite of death or long-term ( X 18 months) major neurodevelopmental disability (cerebral palsy, developmental delay (o2 s.d. below the mean in: Mental Developmental Index score in Bayley Scales for Infant Development II (BSID-II), 18 a cognitive scale score or a language composite scale score on the BSID-III, 18, 19 Griffith assessment, 20 Brunet-Lezine quotient 21 Gesell Child Development Age Scale 22 or Denver II 23 or intellectual impairment (IQ o2 s.d. below mean), blindness (vision o6/60 in both eyes) or sensorineural deafness requiring amplification). Secondary outcomes included a composite of short-term (o18 months) unfavorable outcomes (survival with abnormalities in any of the following: neurodevelopmental exam, neuroimaging or neurophysiologic studies), death before discharge, seizures, hypotension requiring inotropic support after enrolment and length of mechanical ventilation.
Data analysis
Meta-analyses were performed using the Review Manager software (RevMan Version 5.0; Nordic Cochrane Centre, Copenhagen, Denmark) utilizing the Mantel-Haenzel method and a random effects model. 24 Risk ratios (RRs) with 95% confidence intervals (CIs), were calculated. The x 2 -test was applied to detect between-studies heterogeneity and I 2 values were calculated to assess statistical heterogeneity. Values of I 2 o25% were considered low, I
2 475% were considered high and I 2 between 25 and 75% were considered moderate in heterogeneity. 25 
RESULTS
Thirteen studies were evaluated for eligibility ( Figure 1 ). Magnesium for newborns with hypoxic-ischemic encephalopathy M Tagin et al A composite measure of no neurologic abnormality, normal neuroimaging findings, normal electroencephalographic findings and oral feeding through sucking at discharge.
Magnesium for newborns with hypoxic-ischemic encephalopathy M Tagin et al quality were included in this review comprising a total of 182 participants. The study details are shown in Table 1 . The study by Fai et al. 26 was excluded as it was deemed to have a high risk of bias with significant methodological limitations including lack of sequence generation, allocation concealment and blinding of outcome assessors. The excluded studies along with reasons for exclusion are shown in Table 2 .
Clinical heterogeneity assessment among included studies Types of participants. The included trials had similar enrollment criteria and all included term newborns (X 37 weeks gestation) with evidence of birth asphyxia (Table 1) .
Intervention. All the included studies used magnesium sulfate given within 24 h of birth. The dose of magnesium varied between studies: 250 mg kg -1 every 24 h for three doses in two studies, 27, 28 250 mg kg -1 followed by two doses of 125 mg kg -1 every 24 h for two doses in another two studies 29, 30 and a single dose of 250 mg kg -1 in one study. 31 Magnesium was administered over 30 min in one study, 30 over 1 h in three studies [27] [28] [29] and was not clear in one study. 31 There was concomitant use of dopamine 5 mg kg -1 min -1 in one study to guard against hypotension. 28 Methodological quality of the included studies All the included studies were assessed as recommended by the Cochrane review guidelines. 17 Assessment of the risk of bias among the included studies is reported in Table 1 . Overall, the methodology of the five included studies was acceptable. The assessment of publication bias was planned but not performed because of the low number of included studies.
Outcome measures Details of the primary outcome of the included studies are shown in Table 1 . The primary outcome as determined for this systematic review of death or moderate-to-severe disability at 18 months was assessed in one study. 30 The other four included studies had variable short-term primary outcomes (Table 1 ). All the studies reported data on mortality before discharge from the hospital.
There was no difference in the composite primary outcome of death or moderate-to-severe neurodevelopmental disability at age 18 months (one study, 22 participants, RR 0.81, 95% CI 0.36 to 1.84) between the magnesium and the control groups. Magnesium reduced the risk of unfavorable short-term composite outcome (three studies, 98 participants, RR 0.48, 95% CI 0.30 to 0.77; I 2 ¼ 0%; Figure 2 ) when compared to the control group. There was no difference between newborns treated with magnesium and controls in mortality (five studies, 182 participants, RR 1.39, 95% CI 0.85 to 2.27; I 2 ¼ 0%; Figure 3 ), hypotension (two studies, 92 participants, RR 1.28, 95% CI 0.69 to 2.38; figure not shown) or seizures (five studies, 182 participants, RR 0.84, 95% CI 0.59 to 1.19; I 2 ¼ 0%; Figure 4 ). 
40
Animal study Evans et al. 36 No published data-the study was terminated because of the wrong dosage Fai et al. 26 (Chinese) Significant methodological limitations including Risk of bias assessment Less than transparent allocation method, although described as ''random assignment'' . Males are significantly more than Females (50 Males versus 26 Females), which may be due to selection bias. Non-blinded assessor of outcome Internal validity issues: (a) Unexplained discrepancies in the time of enrollment among the included newborns (62 were o24-h old and 14 were between 24 and 72-h old at enrollment). (b) The dose difference from the preceding dosage studies (25 mg kg -1 for 10 days) 
(German)
Antenatal magnesium to pregnant mothers rather than postnatal Gathwala et al.
42
No clinical outcome reported Ichiba et al.
32
No control group Khashaba et al. 43 Published only in abstract and the original data were already included in another publication (included in the review) Maroszynska et al. 
DISCUSSION
This systematic review of the randomized controlled trials in newborns with HIE who received magnesium therapy compared to controls shortly after birth did not yield sufficient data to allow analysis of the primary outcome of mortality or long-term neurodevelopment as it was only evaluated in one study with a small sample size. 30 In a cohort study without controls, Ichiba et al. 32 reported normal neurodevelopmental outcome at 18 months of age in 22 out of 30 newborns (73%) with birth asphyxia treated with magnesium; their results show potential for magnesium in treating newborns with HIE in the long-term at 18 months.
The results from this review indicate an improvement in the short-term composite outcome of survival with abnormalities in any of the following: neurodevelopmental exam, neuroimaging or neurophysiologic studies. Evaluation of short-term outcomes is not necessarily indicative of long-term outcomes and long-term outcomes must be evaluated.
The caveat of using magnesium is the fear of potential transient complications such as systemic hypotension, respiratory depression and feeding difficulties. 33, 34 These side effects were not consistently evaluated in the studies included in the current review. In the two studies that evaluated hypotension requiring inotropic support, there was no difference between the magnesium and the control groups. 27, 31 Ichiba et al. 28 reported the use of dopamine as a proactive pragmatic step to guard against systemic hypotension in their cohort. Respiratory depression as an outcome is difficult to evaluate as it might be due to birth asphyxia rather than from the use of magnesium. We planned to evaluate the length of mechanical ventilation as a more precise outcome; however, it was not evaluated in the included studies. Khashaba et al. 31 reported no difference between the magnesium and the control groups in newborns who required mechanical ventilation at 72 h of age despite the observation that there were tendency toward the use of more mechanical ventilation in the magnesium group (34.8% versus 16.7%). It is important to note that the sample sizes in the included studies were small and there was insufficient power to detect a potentially clinically important differences.
The therapeutic window for magnesium or in other words the window of opportunity for magnesium to act as a neuroprotective agent is unknown. In the included studies, magnesium was used in the first 24 h of life. Khashaba et al. 31 demonstrated that the excitatory neurotransmitters, glutamate and aspartate, are released in the cerebrospinal fluid of asphyxiated newborns immediately after birth and decline by 72 h. As the role of magnesium is to block the NMDA receptors in the face of increased excitatory neurotransmitters, it seems prudent to initiate magnesium therapy as soon as possible after the hypoxic insult for newborns with moderate-to-severe HIE.
From the current review, we could not evaluate whether magnesium modified the severity of encephalopathy but such evaluation deserves further investigation. Khashaba et al. 31 showed that the initial concentrations of glutamate and aspartate correlated with the severity of HIE, which indicate that a differential treatment effect is possible among newborns with moderate compared with newborns with severe HIE.
The strengths of this review include a comprehensive search strategy, explicit inclusion and exclusion criteria, and evaluation of clinically important outcomes. It is also important to note that this review provides the most complete evidence around the use of magnesium as a single treatment modality for neuroprotection in newborns with HIE. It is not expected, for ethical reason, to randomize any new patients with moderate-to-severe HIE without having therapeutic hypothermia as the foundation of treatment since its effectiveness and safety has been established and is currently recommended as the standard of care for newborns with moderate-to-severe HIE. 7, 35 Limitations of this review include the small number of eligible studies, each of which enrolled a small number of infants. The primary outcome in this review was measured in only one of the five included studies and had insufficient power to detect clinically important differences. The secondary outcomes of the current review were heterogeneously measured with each outcome not measured in all the included studies. These limitations preclude any strong conclusions from the current review.
Publication bias may exist and there is a likelihood that negative reports may not have been published. During our literature search, we found that the RAST study (Randomized Asphyxia Study) was not completed; there were no published data about the enrolled patients mainly because of the use of the wrong dosage of magnesium than what was intended (personal communication with the investigators). 36 Statistical heterogeneity was not an issue in any of the analyses but there were clinical heterogeneities among the included studies (the dosage and frequency of magnesium, time of enrollment, methodological quality and length of follow-up). We acknowledge these limitations and therefore interpret the results from this review with caution.
Owing to the heterogeneity of outcomes reported by the studies, we used a composite outcome to pool the most clinically relevant short-term outcomes among those reported by the studies. Although the individual components of the composite outcome may not be equivalent, using a composite outcome increased the statistical efficiency and enabled us to answer a question that could not otherwise be tackled especially with small and short-term studies. We tried to provide an evidence from the daily clinical practice, which is directly related to the primary objective of the current review about the use of magnesium in newborn with HIE. Hence, this review highlights the need for further delineation on this aspect in future trials.
Despite the major contribution of therapeutic hypothermia to improve clinical outcomes, the overall outcomes of HIE remain poor, 7 and it is unlikely that a single therapy will effectively inhibit the complex and dynamic cascade of hypoxic ischemic injury. Further opportunity for research exists for magnesium as a low cost and accessible drug to act as an adjuvant treatment to therapeutic hypothermia. Animal studies demonstrated that postischemic treatment with modest hypothermia and magnesium is more effective than either treatment used alone. 37, 38 Moreover, antenatal magnesium administration to women at risk of preterm birth has been shown to reduce the risk of cerebral palsy, and is now established as a neuroprotective agent. 39 The information provided in this review offers promise for magnesium in the future for clinical applications to contribute in improving outcomes for newborns with moderate-to-severe HIE.
Future trials of magnesium as a treatment modality for newborns with HIE should have a carefully written protocol with a standardized measurement of interim outcomes, and careful monitoring and aggressive management for important adverse effects including systemic hypotension, respiratory depression and feeding intolerance. Future studies should have sufficient sample sizes to detect clinically important differences in the primary long-term outcome and safety. Whether severity of encephalopathy modified the effect of magnesium on clinical outcomes and what is the best timing of magnesium administration for purposes of maximum efficacy also needs to be evaluated.
CONCLUSIONS
There is insufficient evidence to determine if magnesium therapy given shortly after birth to newborns with HIE reduces death or moderate-to-severe disability. The improvement in short-term outcomes without significant increase in adverse effects supports the need for further adequately powered trials to determine if there are long-term benefits of magnesium and to confirm its safety. Mortality should be monitored closely in all future trials involving magnesium therapy for newborns with HIE. In the current review, the results, although statistically insignificant for mortality between the magnesium and the control groups, showed a trend toward an increase in mortality in the magnesium group.
